Document is current
Any future updates will be listed below
-
Authors
Hurley, James H. https://orcid.org/0000-0001-5054-5445
Coyne, Alyssa N. https://orcid.org/0000-0002-3658-5325
Miączyńska, Marta https://orcid.org/0000-0003-0031-5267
Stenmark, Harald https://orcid.org/0000-0002-1971-4252
- License Information
-
More Information
Article History
Received: 8 October 2024
Accepted: 27 March 2025
First Online: 25 June 2025
Competing interests
: A.N.C. is an inventor (50%) on US patent application number 63/111,882 filed by Johns Hopkins University on methods to modulate CHMP7 expression as a therapy for neurodegeneration. A.N.C. is an inventor (90%) on US patent application number PCT/US2025/015434 filed by Johns Hopkins University on methods to modulate CHMP2B expression as a therapy for neurodegeneration. J.H.H. is a co-founder and shareholder of Casma Therapeutics, receives research funding from Hoffman-La Roche and has consulted for Corsalex. J.H.H. is an inventor on US patent application number 63/786,223 filed by the University of California, Berkeley on selective inhibitors of VPS4B and VPS4A and their use. M.M. and H.S. declare no competing interests.
